Technical Analysis for ALRN - Aileron Therapeutics, Inc.

Grade Last Price % Change Price Change
F 2.76 -2.13% -0.06
ALRN closed down 2.13 percent on Wednesday, November 20, 2024, on 1.27 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish -2.13%
Lower Bollinger Band Walk Weakness -2.13%
Inside Day Range Contraction -2.13%
Wide Bands Range Expansion -2.13%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High about 21 hours ago
Outside Day about 21 hours ago
Up 10% about 21 hours ago
Up 5% about 21 hours ago
60 Minute Opening Range Breakout about 21 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aileron Therapeutics, Inc. Description

Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Solid Tumors Tumor Inflammation Molecular Biology Lymphoma Cell Biology Metabolic Disease Oncogenes Peptides Hematological Malignancies Proteins P53 Tumor Suppressor Genes Treatment Of A Range Of Cancer Tumor Suppressor

Is ALRN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.42
52 Week Low 1.61
Average Volume 90,598
200-Day Moving Average 3.75
50-Day Moving Average 3.48
20-Day Moving Average 3.62
10-Day Moving Average 3.32
Average True Range 0.39
RSI (14) 31.97
ADX 22.52
+DI 8.27
-DI 22.50
Chandelier Exit (Long, 3 ATRs) 3.24
Chandelier Exit (Short, 3 ATRs) 3.75
Upper Bollinger Bands 4.49
Lower Bollinger Band 2.75
Percent B (%b) 0.0
BandWidth 48.06
MACD Line -0.17
MACD Signal Line -0.03
MACD Histogram -0.1469
Fundamentals Value
Market Cap 13.48 Million
Num Shares 4.89 Million
EPS -2.85
Price-to-Earnings (P/E) Ratio -0.97
Price-to-Sales 0.00
Price-to-Book 2.09
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.54
Resistance 3 (R3) 3.57 3.34 3.41
Resistance 2 (R2) 3.34 3.14 3.33 3.37
Resistance 1 (R1) 3.05 3.02 2.94 3.02 3.32
Pivot Point 2.82 2.82 2.76 2.81 2.82
Support 1 (S1) 2.53 2.62 2.42 2.50 2.20
Support 2 (S2) 2.30 2.50 2.29 2.15
Support 3 (S3) 2.01 2.30 2.11
Support 4 (S4) 1.98